International Journal of Preventive Medicine Research, Vol. 1, No. 1, April 2015 Publish Date: Apr. 8, 2015 Pages: 12-16

Characteristics of Ischemic Heart Disease Patients Dying with Drug Induced Bone Marrow Suppression

Muhammad Irfan1, *, Ghulam Mustafa Aftab2, Muhammad Arif Nadeem1, Irfan Bhatti1, Tariq Suleman1, Khalil Ahmed1, Muhammad Naseem Akhtar1, Attique Abou Bakr1

1Medicine department, Services Institute of Medical Sciences, Services Hospital, Lahore, Pakistan

2Medical Student, CMH Medical College, Lahore, Pakistan

Abstract

Objective: To determine characteristics of Ischemic Heart Disease (IHD) patients dying with drug induced bone marrow suppression. Study Design: Cross-sectional Study. Place and Duration of Study: Medical Unit 3, Services Hospital Lahore, from December 2011 to February 2012. Methodology: Patients of IHD taking medication from Punjab Institute of Cardiology (PIC), Lahore presented with mucosal bleeding (PIC syndrome). The clinical data and laboratory assessment was made, analyzed and Fisher exact test applied to find any significance at 5% level. Results: Amongst 86 patients with Platelet count <100,000/mm3, 25.6% patients died while 74.4% discharged. Death group of patients had statistically significant association with Fever (p = 0.002), Diabetes Mellitus (p = 0.002), abnormal ALT (p = 0.000) and abnormal serum creatinine (p = 0.026), while recovered group had significant association with current no use of clopidogrel (p = 0.000), calcium channel blockers (p = 0.000) and nitrates (p = 0.017). However, gender, age, bleeding, past history of Dengue, Hemoglobin, White cell count, Platelet count, INR, current use of aspirin, beta-blockers, ACE inhibitors and statins had no significance with hospitalization outcome. The risk of bleeding was >4.115 times in patients using calcium channel blockers. Conclusion: A large number of IHD patient had died during the epidemic of drug induced bone marrow suppression and death was common among patients with diabetes, fever, abnormal ALT and abnormal creatinine. However recovery was more among patients not using clopidogrel, calcium channel blockers and nitrates. The risk of bleeding was positively correlated with use of calcium channel blockers.

Keywords

Ischemic Heart Disease, PIC Syndrome, Bone Marrow Suppression, Death


1. Introduction

Bone marrow failure1is a group of disorders that may manifest as either single cytopenia (e.g., erythroid, myeloid, or megakaryocytic) or pancytopenia.2 It can be either inherited or acquired.3Acquired bone marrow failure can be caused by drugs,4 chemicals,5 radiation,6viral infection7, vitamin deficiencies, immune dysfunction and idiopathic.

Because the bone marrow is the manufacturing factory of blood cells8, the suppression of its activity causes their deficiency. This condition can rapidly lead to life-threatening infections, as the body cannot produce leukocytes in response to invading bacteria and viruses, as well as anemia due to a deficiency of red blood cells and spontaneous severe bleeding due to lack of platelets.

The incidence of acquired aplastic anemia in Europe and North America is estimated to be two per million populations per year as compared to its higher rates in Asia.9

In December 2011, hundreds of Ischemic Heart Disease (IHD) patients taking free medicines from Punjab Institute of Cardiology (PIC) started presenting in emergency department of Services Hospital, Lahore with bicytopenia or pancytopenia, and related complications and a significant number of these patients died. The drug induced bone marrow suppression was suspected and the condition was then labeled as "PIC Syndrome". Later Pyrimethamine contamination in Nitrate was found as the culprit drug.10

This study was conducted to reveal the characteristics of Ischemic Heart Disease patients dying with drug induced bone marrow suppression after receiving medicines from PIC, so that some significant predictors to death can be found that may help the doctors in future during such disaster.

2. Methodology

This study was carried out at the Medical unit3, Services Hospital, Lahore from December 2011 to February 2012. Purposive sampling technique was used and all the admitted 86 patients of both sexes with history of Ischemic Heart Disease and taking free medications from the PIC and having bone marrow suppression of short duration were included. On the other hand, patients with past history of bone marrow suppression of long duration were excluded. Informed consent was taken from patients recruited and their demographic data was recorded.

The clinical as well as laboratory assessment was made. Oral medications provided from the PIC were withdrawn. Complete blood count along with renal function tests and liver function tests were performed. The collected data was analyzed on SPSS version 15.

The descriptive analysis of the collected data was done. Age, Hemoglobin concentration, White cell count , Platelet count, serum creatinine, ALT and INR were quantitative variables, while gender, fever, bleeding, history of diabetes mellitus, hypertension, past history of Dengue, current use of aspirin, clopidogrel, calcium channel blockers, nitrates , diuretics, beta-blockers, ACE inhibitors, statins and hospitalization outcome were the qualitative variables. Investigational data was interpreted in negative or positive values. For quantitative variables, means and standard deviations were calculated and for qualitative variables, frequencies and percentages were computed. Chi-square test (Fisher exact test) was applied to find any association of factors at 5% level of significance. The means of quantitative variable were compared with Hospitalization outcome through Independent T test.

3. Results

All admitted 86 patients of Ischemic Heart Disease (IHD) with platelet count below 100,000/mm3 were enrolled, 59 were males and 27 females. The mean age (years) of patients was 59.47 ± 9.76, the mean hemoglobin (g/dl) 10.32 ± 2.41, the mean white cell count (x 103/mm3) 2.89±2.38, the mean platelet count (x 103/mm3) 23.24 ± 19.82, the mean ALT (IU/ml) 28.00 ± 17.63, the mean serum creatinine (mg/dl) 1.10 ± 0.65 and the mean INR was 1.18 ± 0.41 (table 1).

Amongst 86 patients, 22 patients (25.6%) were died during hospitalization while remaining 64 (74.4%) were recovered and discharged (table 2a).

The group of patients who died during hospitalization was statistically correlated with the age of patients, gender, history of fever, bleeding, diabetes mellitus, hypertension, past history of dengue, hemoglobin concentration, white cell count, platelet count, ALT, serum creatinine, INR, use of aspirin, clopidogrel, diuretics, beta-blockers, ACE-inhibitors, calcium channel blockers, nitrates and statins.

On comparing the means of quantitative variable with hospitalization outcome through Independent T test (table 1), we found that the mean creatinine of expired patients group (1.36 ± 1.06) was more than the mean creatinine of discharged patients group (1.01 ± 0.41), and the association was statistically significant (p=0.026). The comparison of the rest of the quantitative variables with hospitalization outcome was statistically insignificant. However, the mean age of expired patients (62.50 ± 10.84) was more than the mean age of discharged patients (58.42 ± 9.22) with p value of 0.091.

Among patients who had fever, 52.2% (12 out of 23) died during hospitalization, while among those who had no fever, 84.1% (53 out of 63) got recovered and were discharged. The association was statistically significant (p=0.002).

Among diabetic patients, 52.2% (12 out of 23) died during hospitalization, while among non-diabetic patients, 84.1% (53 out of 63) got recovered and were discharged. The association was also statistically significant (p=0.002).

Among patients who had abnormal ALT, 56.7% (17 out of 30) died during hospitalization, while among those who had normal ALT, 91.1% (51 out of 56) got recovered and were discharged. The association was statistically significant (p=0.000).

Among patients who were not using clopidogrel, 95.5% patients (42 out of 44) got recovered and were discharged from hospital, while 4.5% (2 out of 44) died. The association was also statistically significant (p=0.000).

Among patients who were not using calcium channel blockers, 91.5 % patients (43 out of 47) got recovered and were discharged from hospital, while 8.5% (4 out of 47) died. The association was also statistically significant (p=0.000)

Similarly, among patients who were not using nitrates, 100% patients (14 out of 14) got recovered and were discharged from hospital, while none died. The association was also statistically significant (p=0.017).

The risk of bleeding was 4.115 times more in group of patients who were using calcium channel blockers. However, use of aspirin and clopidogrel, history of dengue and hypertension, low platelets and deranged INR did not favor the risk of bleeding in these patients. (Table 3)

Table 1. Comparison of quantitative variables with Hospitalization outcome through Independent-Samples T test (n=86).

Quantitative variables Minimum Maximum Discharged Patients Expired Patients Total p-value
Mean ± SD Mean ± SD Mean ± SD
Age of patients (years) 36 80 58.42±9.22 62.50±10.84 59.47±9.76 0.091
Hemoglobin conc. (g/dl) 0.6 15.4 10.55±2.50 9.68±2.06 10.32±2.41 0.147
WBC count (x103/mm3) 0.6 13.0 3.06±2.49 2.38±1.98 2.89±2.38 0.252
Platelet count (x103/mm3) 1 99 24.14±20.65 20.64±17.37 23.24±19.82 0.478
Serum Creatinine (mg/dl) 0.1 5.3 1.01±0.41 1.36±1.06 1.10±0.65 0.026
INR 0.1 3.7 1.16±0.40 1.25±0.42 1.18±0.41 0.373

Table 2a. Qualitative Factors associated with Deaths of Ischemic Heart Disease patients dying with Drug induced bone marrow suppression (n=86).

Qualitative variables Discharged patients (n=64) Died patients (n=22) Likelihood Ratio p-value
Gender:     2.613 0.116
Male Female 17 (63.0%) 47 (79.7%) 10 (37.0%) 12(20.3%)
Fever:     10.831 0.002
Yes No 11 (47.8%) 53(84.1%) 12 (52.2%) 10 (15.9%)
Bleeding:     3.676 0.104
Yes No 51 (70.8%) 13(92.9%) 21 (29.2%) 1 (7.1%)
Past history of Dengue:     0.595 1.000
Yes No 1 (100%) 63(74.1%) 0 (0%) 22 (25.9%)
Hypertension:     1.289 0.314
Yes No 38 (70.4%) 26(81.2%) 16 (29.6%) 6 (18.8%)
Diabetes mellitis:     10.831 0.002
Yes No 11 (47.8%) 53 (84.1%) 12 (52.2%) 10 (15.9%)
ALT     23.052 0.000
Abnormal Normal 13 (43.3%) 51 (91.1%) 17 (56.7%) 5 (8.9%)

Table 2b. Qualitative Factors associated with Deaths of Ischemic Heart Disease patients dying with Drug induced bone marrow suppression (n=86).

Qualitative variables Discharged patients (n=64) Died patients (n=22) Likelihood Ratio p-value
Current use of Aspirin:     6.350 0.058
Yes No 54 (71.1%) 10 (100%) 22 (28.9%) 0 (0%)
Current use of Clopidogrel:     23.404 0.000
Yes No 22 (52.4%) 42 (95.5%) 20 (47.6%) 2 (4.5%)
Current use of Diuretics:     1.987 0.222
Yes No 11 (61.1%) 53 (77.9%) 7 (38.9%) 15 (22.1%)
Current use of Beta-blockers:     0.048 1.000
Yes No 42 (73.7%) 22 (75.9%) 15 (26.3%) 7 (24.1%)
Current use of ACE Inhibitors:     0.064 0.810
Yes No 34 (75.6%) 30 (73.2%) 11 (24.4%) 11 (26.8%)
Current use of Calcium channel blockers: 16.610 0.000
Yes No 21 (53.8%) 43 (91.5%) 18 (46.2%) 4 (8.5%)
Current use of Nitrates:     9.173 0.017
Yes No 50 (69.4%) 14 (100%) 22 (30.6%) 0 (0%)
Current use of Statins:     1.289 0.437
Yes No 56 (72.7%) 8 (88.9%) 21 (27.3%) 1 (11.1%)

Table 3. Qualitative Factors predicting the bleeding in Ischemic Heart Disease patients with Drug induced bone marrow suppression (n=86).

Qualitative variables Occurrence of Bleeding Likelihood Ratio p-value
Yes (n=72) No (n=14)
Current use of Aspirin:     1.349 0.356
Yes No 65 (85.5%) 7 (70.0%) 11 (14.5%) 3 (30.0%)
Current use of Clopidogrel:     1.168 0.384
Yes No 37 (88.1%) 35 (79.5%) 5 (11.9%) 9 (20.5%)
Current use of Calcium channel blockers:     4.115 0.077
Yes No 3 (7.7%) 11 (23.4%) 36 (92.3%) 36 (76.6)
Past history of Dengue:     0.358 1.000
Yes No 1 (100.0%) 71(83.5%) 0 (0.0%) 14 (16.5%)
Hypertension:     0.551 0.556
Yes No 44 (81.5%) 26(87.5%) 10 (18.5%) 4 (12.5%)
Platelet count:     0.643 0.726
>10000/mm3 <10000/mm3 55 (82.1%) 17(89.5%) 12 (17.9%) 2 (10.5%)
INR     0.002 1.000
>1.5 < 1.5 10 (83.3%) 62 (83.8%) 2 (16.7%) 12 (16.2%)

4. Discussion

The clinical presentation of drug induced cytopenia is variable and symptoms and signs are due to involvement of either of the three cell lineages.11 The drugs responsible for bone marrow suppression include phenylbutazone, chloramphenicol,12 gold13, sulfonamides, Felbamate 14, nifedipine 15, methotrexate16, pyrimethamine 17 and many more drugs. Pyrimethamine causes, as it was found the culprit,10 reversible pancytopenia (megaloblastic anemia, leucopenia, agranulocytosis, and thrombocytopenia) secondary to depletion of folic acid stores, generally prevented with co-administration of leucovorin.18

In our study, it was found that cytopenias were not directly related with death of these ischemic heart disease patients, rather comorbid illnesses like diabetes mellitus and failure of vital organs like liver and kidneys during that event of bone marrow suppression were important. Anemia, leucopenia and thrombocytopenia were statistically not significant in patients who died (p=0.130, p=0.759, p=1.000 respectively). However, diabetic patients died more significantly (p=0.002). We found that presence of leucopenia (WBC<4000/mm3) was not significant in death group. However, fever, in the occurrence of which leucopenia may had played a role, was statistically significant in those patients died (p=0.002).

Among liver function tests19, abnormal ALT had played a significant role in deaths of these patients (p=0.000), while abnormal INR was not statistically significant (p=0.494). This might be due to increase in ALT caused by liver injury and increase in INR in majority of these patients might be iatrogenic caused by anticoagulant medicines used like marevan. Similarly, increased serum creatinine was significant in death group (p=0.026). All these facts had indicated that vital organ involvement like liver and kidneys had played significant role in deaths of these IHD patients.

The mean age of died patients was more than discharged patients, as it was difficult for these old patients to sustain the stress of bone marrow suppression.

Absence of some of these drugs in the management of these IHD patients had played a role in hospitalization outcome. Among patients who were not using clopidogrel, 95.5% recovered and discharged, while 4.5% died (p=0.000). Among patients who were not using calcium channel blockers, 91.5% recovered and discharged, while 8.5% died (p=0.000) and similarly patients who were not using nitrates, 100%patients got recovered and discharged, while none died (p=0.017). These findings were indicative of a fact that those patients who were not using these medicines had survived.

It was found that anti-malarial drug, Pyrimethamine contamination in nitrate was responsible10 for bone marrow suppression, however our study showed that cytopenia was not significantly related to deaths and survival of these patients, rather diabetes, fever, vital organ damage and no use of some of these drugs had played the role in deaths and survival of these patients.

Scientifically the forensic analysis20 including postmortem of these died patients and chemical studies of the specimens would have been carried out to assess the exact cause of death but practically it was not done and only toxic levels of the contamination i.e. Pyrimethamine was assessed and its clinical implications were noted.

5. Conclusion

A large number of patients with history of Ischemic Heart Disease and taking oral medications from the PIC, Lahore died during that event of drug induced bone marrow suppression. Death was more likely among patients who were diabetic, and had fever, abnormal ALT and abnormal creatinine. However recovery was more common among patients who were not using clopidogrel, calcium channel blockers and nitrates. The risk of bleeding in our patients was positively correlated to the use of calcium channel blockers. In future the strict vigilance on the system of purchase, storage, periodical inspection and dispensing of the drugs in the hospital pharmacy must be carried out to avoid such disasters.

References

  1. Bunch C. Bone marrow failure. Medicine International 1995; 10: 495-9.
  2. Rehman H, Fazil M, Khan FM. The etiological pattern of pancytopenia in children upto 15 years. Pak armed forces med J 2003; 53: 183-7.
  3. Guinan EC. Acquired aplastic anemia in childhood. Hematol Oncol Clin North Am 2009; 23:171.
  4. Handoko KB, Souverein PC, van Staa T. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006; 47:1232.
  5. Powars D. Aplastic anemia secondary to glue sniffing. N Engl J Med 1965; 273:700.
  6. Lange RD, Wright SW, Tomonaga M. Refractory anemia occurring in survivors of the atomic bombing in Nagasaki, Japan. Blood 1955; 10:312.
  7. Hadzic N, Height S, Ball S. Evolution in the management of acute liver failure-associated aplastic anaemia in children: a single centre experience. J Hepatol 2008; 48:68.
  8. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6:93.
  9. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica 2008; 93:489.
  10. Cox A. Pyrimethamine Poisoning in Pakistan. Available at: http://www.blacktriangle.org/blog/pag 2420.
  11. Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant 2010; 16:S119.
  12. Wallerstein RO, Condit PK, Kasper CK, et al. Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 1969; 208:2045.
  13. Kay AG. Myelotoxicity of gold. Br Med J 1976; 1:1266.
  14. Brodie MJ, Pellock JM. Taming the brain storms: felbamate updated. Lancet 1995; 346:918.
  15. Laporte JR, Ibanez L, Ballarin E. Fatal aplastic anaemia associated with nifedipine. Lancet 1998; 352:619.
  16. Unena SG, Molina JF, Garcia CD. Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39 (2): 272-6.
  17. Waxman S, Herbert V. Mechanisms of pyrimethamine-induced megaloblastosis in human bone marrow. N Engl J Med1969; 28: 1316–1319.
  18. Chute JP, Decker CF, and Cotelingam J. Severe Megaloblastic Anemia Complicating Pyrimethamine Therapy. Ann Intern Med 1995; 122(11):884-5.
  19. Limdi J K, Hyde G M. Evaluation of abnormal liver function tests. Postgrad Med J 2003; 79: 307–12
  20. Carrier B. Data Analysis. In: File System Forensic Analysis. 1st ed. Indiana: Crawfordsville; 2005:16-7.

600 ATLANTIC AVE, BOSTON,
MA 02210, USA
+001-6179630233
AIS is an academia-oriented and non-commercial institute aiming at providing users with a way to quickly and easily get the academic and scientific information.
Copyright © 2014 - 2016 American Institute of Science except certain content provided by third parties.